Redeye provides its review of Acarix following the release of the Q3 report, which showed revenue ahead of our estimates, while costs and EBIT came in broadly in line. We are also encouraged by the continued progress in the Middle East, where the company has now gained regulatory approval for the CADScor System in both the UAE and Saudi Arabia. On the back of the report, we have moved our Middle East sales into H1 2027e, while highlighting that our outlook on the company remains intact. We reiterate our fundamental valuation (base case) and Fair Value of SEK0.4, with the stock now screening as “Attractively Priced”.
LÄS MER
